M. Barrett

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Mitch Dowsett, Gerhardt Attard, Johann S de Bono, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiation for rectal cancer: current methods.

M. Barrett, 1998, Seminars in surgical oncology.

The Collaborative UK ECMO Trial: Follow-up to 1 Year of Age

M. Mugford, D. Bayliss, J. Whyte, 1998, Pediatrics.

Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle.

W. Steward, R. Molife, M. Barrett, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer associated haemolytic uraemic syndrome developing prior to treatment with cytotoxic agents.

J. Mann, D. Milford, F. Raafat, 1993, Medical and pediatric oncology.

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

R. Plummer, I. Judson, S. Kaye, 2007, Clinical Cancer Research.

Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor

M. Dowsett, D. Dearnaley, C. Parker, 2007 .

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

C. Iacobuzio-Donahue, A. Jimeno, M. Hidalgo, 2010, British Journal of Cancer.

The Effect of Complementary Therapies on the Treatment of Chemotherapeutic Induced Nausea and Vomiting: A Systematic Review

M. Barrett, A. Siegenthaler, K. Sickel, 2018 .

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

M. Dowsett, D. Dearnaley, C. Parker, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical experience of marketed Levetiracetam in an epilepsy clinic—a one year follow up study

T. Betts, H. Yarrow, L. Greenhill, 2003, Seizure.